Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are members of a family of cytokines that regulate the proliferation and differentiation of a variety of cell types. In this report, cDNA probes specific for OSM and LIF were hybridized to DNA from somatic cell hybrids containing defined regions of human chromosome 22, and the gene for human OSM was found to segregate with that of LIF. Southern analysis of high-molecular-weight DNA that had been digested with rare-cutting restriction enzymes and analyzed by pulsed-field gel electrophoresis showed identical hybridization patterns with both probes. The probes also identified common cosmid clones on high-density cosmid filters prepared from chromosome 22-specific flow-sorted cosmid libraries. Restriction and Southern analyses of six cosmid clones established a contig of approximately 100 kb surrounding the genes for OSM and LIF. The OSM and LIF genes are tandemly arranged in the same transcriptional orientation separated by approximately 10 kb. The direction of gene transcription is telomeric to centromeric, with the OSM gene located upstream of the LIF gene. Our studies define a new gene cluster on chromosome 22 and provide strong evidence that OSM and LIF have resulted from duplication of a common ancestral gene.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/geno.1993.1294 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diversity of Microglia-Derived Molecules with Neurotrophic Properties That Support Neurons in the Central Nervous System and Other Tissues.
Molecules
November 2024
Laboratory of Cellular and Molecular Pharmacology, Department of Biology, University of British Columbia, Okanagan Campus, Kelowna, BC V1V 1V7, Canada.
Microglia, the brain immune cells, support neurons by producing several established neurotrophic molecules including glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). Modern analytical techniques have identified numerous phenotypic states of microglia, each associated with the secretion of a diverse set of substances, which likely include not only canonical neurotrophic factors but also other less-studied molecules that can interact with neurons and provide trophic support. In this review, we consider the following eight such candidate cytokines: oncostatin M (OSM), leukemia inhibitory factor (LIF), activin A, colony-stimulating factor (CSF)-1, interleukin (IL)-34, growth/differentiation factor (GDF)-15, fibroblast growth factor (FGF)-2, and insulin-like growth factor (IGF)-2.
View Article and Find Full Text PDFLeukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis.
Proc Natl Acad Sci U S A
December 2024
Department of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA 02115.
Article Synopsis
- Fibrosis contributes to serious damage in organs, but treatments targeting specific activators have often failed, leading researchers to focus on the leukemia inhibitory factor receptor (LIFR) as a key player in fibrotic diseases like idiopathic pulmonary fibrosis (IPF).
- In IPF, myofibroblasts highly express LIF, and fibroblasts in key fibrotic areas coexpress LIF and LIFR, demonstrating LIFR's role in amplifying signals from other fibrotic drivers like TGFβ1, IL-4, and IL-13.
- Blocking LIFR reduces the activation of profibrotic genes and highlights LIFR's function as a master amplifier of harmful signals
Elastin-like Recombinamers as a Biotechnological Platform for the Development of Cytokine-Functionalized Materials.
ACS Omega
November 2024
CBMA (Centre of Molecular and Environmental Biology)/ARNET (Aquatic Research Network) Associate Laboratory, Department of Biology, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are pleiotropic cytokines from the interkeukine-6 family, associated with several disorders, and present significant potential in biomedicine. However, their therapeutic use is highly constrained by factors such as short circulating half-life and narrow therapeutic window. The conjugation of cytokines with elastin-like recombinamers (ELR) holds the potential to circumvent these limitations due to the ability of self-assembling upon a thermal stimulus, remarkable biocompatibility, and ease of processing.
View Article and Find Full Text PDFRapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
Roles of leukemia inhibitory factor receptor in cancer.
Int J Cancer
January 2025
Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China.
Article Synopsis
- The Leukemia Inhibitory Factor Receptor (LIFR) works with another protein called gp130 to help cells respond to signals that can affect cell growth and movement.
- LIFR can have different effects on tumors, sometimes helping them grow and other times making them shrink, depending on the type of tumor and how the signals are sent.
- Because LIFR is found in many cancer cells and plays a big role in how tumors develop, it might be a good target for new treatments against cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!